Since the importance of drug target residence time was first highlighted more 10 years ago, slow binding kinetics has received much attention in the drug discovery literature, and indeed within pharmaceutical research. However, the residence concept as presented in most papers is supported by rather misleading simulations and arguments, and by examples where compounds are taken out of their pharmacokinetic context. Moreover, fast association is typically more desirable than slow, and advantages of long residence time, notably a potential disconnect between pharmacodynamics (PD) and pharmacokinetics (PK), would be partially or completely offset by slow on-rate. Therefore, plain potency is likely a better predictor of drug development success than is residence time.

自10多年前首次强调了药物靶标停留时间的重要性以来，缓慢的结合动力学已在药物发现文献中以及在药物研究中引起了广泛关注。但是，大多数论文中提出的驻留概念受到误导性的模拟和争论的支持，并且化合物被排除在药代动力学背景之外的例子也得到了支持。而且，快速缔合通常比慢缔合更合乎需要，并且长停留时间的优势，特别是药效学（PD）和药代动力学（PK）之间潜在的脱节，将被缓慢的接通速度部分或完全抵消。因此，与停留时间相比，普通效力可能是药物开发成功的更好的预测指标。